- Home
- RVTY vs MRNA Comparison
RVTY vs MRNA Comparison
Compare RVTY & MRNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RVTY
- MRNA
- Stock Information
- Founded
- RVTY 1937
- MRNA 2010
- Country
- RVTY United States
- MRNA United States
- Employees
- RVTY N/A
- MRNA N/A
- Industry
- RVTY Biotechnology: Laboratory Analytical Instruments
- MRNA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RVTY Industrials
- MRNA Health Care
- Exchange
- RVTY Nasdaq
- MRNA Nasdaq
- Market Cap
- RVTY 13.9B
- MRNA 16.0B
- IPO Year
- RVTY N/A
- MRNA 2018
- Fundamental
- Price
- RVTY $123.98
- MRNA $35.89
- Analyst Decision
- RVTY Buy
- MRNA Hold
- Analyst Count
- RVTY 12
- MRNA 20
- Target Price
- RVTY $133.00
- MRNA $76.35
- AVG Volume (30 Days)
- RVTY 679.3K
- MRNA 10.7M
- Earning Date
- RVTY 01-31-2025
- MRNA 02-20-2025
- Dividend Yield
- RVTY 0.23%
- MRNA N/A
- EPS Growth
- RVTY N/A
- MRNA N/A
- EPS
- RVTY 2.06
- MRNA N/A
- Revenue
- RVTY $2,721,555,000.00
- MRNA $5,081,000,000.00
- Revenue This Year
- RVTY $2.20
- MRNA N/A
- Revenue Next Year
- RVTY $4.98
- MRNA N/A
- P/E Ratio
- RVTY $60.16
- MRNA N/A
- Revenue Growth
- RVTY N/A
- MRNA N/A
- 52 Week Low
- RVTY $97.32
- MRNA $31.94
- 52 Week High
- RVTY $129.50
- MRNA $170.47
- Technical
- Relative Strength Index (RSI)
- RVTY 64.65
- MRNA 40.41
- Support Level
- RVTY $116.60
- MRNA $33.34
- Resistance Level
- RVTY $123.00
- MRNA $35.68
- Average True Range (ATR)
- RVTY 3.48
- MRNA 2.53
- MACD
- RVTY 0.96
- MRNA -0.60
- Stochastic Oscillator
- RVTY 99.59
- MRNA 23.26
About RVTY Revvity Inc.
Revvity provides instruments, tests, services, and software solutions to the pharmaceutical, biomedical, chemical, environmental, and general industrial markets. The company operates in two segments. First, its diagnostics segment includes immunodiagnostics, reproductive health, and applied genomics. Second, its discovery and analytical solutions is composed of life science, industrial, environmental, and food applications. Revvity offers products and services ranging from genetic screening and environmental analytical tools to informatics and enterprise software.
About MRNA Moderna Inc.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.